Patients currently suffering from the human immunodeficiency virus (HIV) are most likely to be treated with AIDS-prevention medications such as the drug Tenofovir - a first-line therapy that, while initially helpful, quickly becomes very ineffective.
This reportedly occurs because the virus mutates to devlop a resitance to these drugs, forcing physicians to move their patients onto more potent medications with many adverse effects.
However, according to a study recently published in The International Journal of Pharmaceutics, researchers have discovered that new drug therapies developed using a molecule called EFdA can potentially help halt the spread of the virus without a high risk of increasing drug resistance.
Authors of the study explained in a recent press release that EFdA was discovered in 2001, when a soy sauce company was attempting to create a new flavor enhancer. When the compound was made, scientists quickly realized it was a "nucleoside analogue" - a type of compound commonly used for viral treatment.
[via - natureworldnews.com]